What central and peripheral neuromodulators are recommended for treating epigastric pain syndrome (EPS) and post‑prandial distress syndrome (PDS)?

Central and Peripheral Neuromodulators for EPS and PDS

Tricyclic antidepressants (TCAs) are the recommended central neuromodulators for both EPS and PDS, started at 10 mg amitriptyline once daily and titrated slowly to 30-50 mg once daily as second-line therapy after acid suppression or prokinetics fail. 1

Treatment Algorithm by Subtype

For Epigastric Pain Syndrome (EPS)

First-line therapy:

• Proton pump inhibitors (PPIs) at standard dose are the initial treatment of choice for EPS 1, 2
• If PPIs fail, consider histamine-2 receptor antagonists (H2RAs) as an alternative acid suppression strategy 1

Second-line central neuromodulators:

• TCAs are strongly recommended as gut-brain neuromodulators when first-line therapies fail 1
• Start at low dose (10 mg amitriptyline once daily) and titrate slowly to maximum 30-50 mg once daily 1
• TCAs are particularly effective for EPS and refractory symptoms 2, 3
• Careful explanation of rationale is required, as patients need counseling about side effect profile 1

Alternative central neuromodulators:

• Antipsychotics (sulpiride 100 mg four times daily or levosulpiride 25 mg three times daily) may be efficacious as second-line treatment 1
• Mirtazapine is supported for FD patients, particularly those with weight loss 2, 3

For Postprandial Distress Syndrome (PDS)

First-line therapy:

• Prokinetics are preferred for PDS, though efficacy varies by drug class and availability 1, 2
• Short course of prokinetics should be used preferentially in PDS-subtype patients 2

Second-line central neuromodulators:

• TCAs remain the recommended central neuromodulator when prokinetics fail 1
• Same dosing strategy: start 10 mg amitriptyline once daily, titrate to 30-50 mg once daily 1
• Mirtazapine is particularly useful for PDS patients with early satiation and weight loss 2, 3
• Fundus-relaxing 5-HT1A agonists are emerging therapies for PDS with early satiation 3

Peripheral Neuromodulators

No specific peripheral neuromodulators are recommended for EPS or PDS in the current guidelines. The term "neuromodulator" in functional dyspepsia management refers primarily to centrally acting agents that modulate pain processing and gut-brain interactions 1, 4.

What NOT to Use

• Selective serotonin reuptake inhibitors (SSRIs) are NOT recommended - insufficient evidence supports their use in FD 2
• Opioids should be avoided to minimize iatrogenic harm in severe or refractory cases 1
• Higher PPI doses should not be pursued as they are not more effective than standard doses 2

Key Clinical Considerations

Initiation location:

• TCAs can be initiated in either primary or secondary care 1
• Requires careful patient education about why antidepressants are being used for gastrointestinal symptoms 1, 4

Mechanism of action:

• Central neuromodulators work by modulating central pain processing, improving mood, and affecting visceral sensitivity 4
• They benefit pain, sleep, and depression in addition to gastrointestinal symptoms 4

Common pitfall:

• Patients may resist antidepressant therapy due to stigma or misunderstanding 1
• Emphasize these are used as "gut-brain neuromodulators" at lower doses than for psychiatric conditions 1, 4

For overlap presentations:

• Approximately 40% of EPS patients have postprandial epigastric pain (pEPS), and 50% of PDS patients report postprandial epigastric pain 5
• Patients with PDS plus postprandial epigastric pain have the most associated gastrointestinal symptoms and may require combination approaches 5